芬兰女性人群中早发性卵巢功能不全的发病率及家族风险
基于芬兰全国登记数据,1988-2017年共5011例早发性卵巢功能不全(POI)女性,计算不同年龄组发病率及时间变化,并匹配对照分析亲属患病风险。15-19岁组发病率自2007年起从7.0升至2015-2017年的10.0/10万女性年,35-39岁组最高但下降;POI女性亲属的POI相对风险为4.6(95%CI 3.3-6.5)。
要点
- 15-19岁女性POI发病率自2007年起从7.0升至2015-2017年的10.0/10万女性年。
- 35-39岁组发病率最高,从1993-1997年的73.8降至2013-2017年的39.9/10万女性年。
- POI女性亲属的POI相对风险为4.6(95%CI 3.3-6.5),较无POI女性亲属显著升高。
核心结论
- POI女性的一级亲属发生POI的风险显著升高,相对风险为4.6(95%CI 3.3-6.5)。
- 提高对风险升高的认识可能促进早期诊断和启动激素替代治疗,或可预防低雌激素水平的不良影响如骨质疏松。
研究设计与样本
- 基于人群的研究,纳入1988-2017年芬兰全国登记的5011例POI女性。
- 从社会保险机构(SII)识别因POI获得激素替代治疗报销的女性,从数字与人口数据服务机构(DVV)为每例POI女性匹配4名人群对照。
- 从DVV识别POI病例和对照的家庭成员,链接SII报销数据以识别其中的POI诊断,采用逻辑回归模型估计POI的家族风险。
主要发现
- 发病率在35-39岁组最高,从1993-1997年的73.8/10万女性年降至2013-2017年的39.9/10万女性年。
- 自2007年起,15-19岁组发病率从7.0升至2015-2017年的10.0/10万女性年。
- 1988-2017年40岁以下女性的POI累积发病率为478/10万女性。
- POI女性亲属的POI相对风险为4.6(95%CI 3.3-6.5),对照为无POI女性的亲属。
- POI女性的社会经济地位和教育水平较对照略低。
临床怎么用
- 作者认为,对有一级亲属诊断为POI的女性,提高对风险升高的认识可能促进早期诊断和启动激素替代治疗,或可预防低雌激素水平的不良影响如骨质疏松。
局限性
- 部分POI女性可能缺乏诊断或报销,但鉴于疾病性质及报销的经济获益,作者推测这些女性仅占少数。
- POI发病率的一些变化可能反映临床实践、治疗及报销标准的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the incidence of premature ovarian insufficiency (POI), has the incidence of POI changed over time, and what is the risk of POI among relatives of POI women? SUMMARY ANSWER: The incidence of POI increased among females aged 15-19 years from 2007 onwards and decreased in older age groups, and among relatives of women with POI the risk of POI is significantly increased. WHAT IS KNOWN ALREADY: So far, there has been no good quality, nationwide studies of the incidence of POI. Early menopause has been associated with the elevated risk of early menopause among relatives, but the knowledge of the familial risk of POI is scarce. Lower socioeconomic status has been associated with lower age at natural menopause. STUDY DESIGN, SIZE, DURATION: Population-based study with 5011 women diagnosed with POI in 1988-2017. The data were collected from national registries and covers POI subjects in entire Finland. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with hormone replacement therapy reimbursement for POI were identified from Social Insurance Institution (SII). We calculated POI incidence in different age groups and studied the changes in the incidence rate over time in 5-year segments. Four population-based controls were selected from the Digital and Population Data Services Agency (DVV) for each POI woman. Family members of the POI cases and controls were identified from the DVV and linked to SII reimbursement data to identify POI diagnoses among them. The familial risk of POI was estimated with a logistical regression model. MAIN RESULTS AND THE ROLE OF CHANCE: The incidence was highest in the 35-39 age group, ranging from 73.8/100 000 women-years in 1993-1997 to 39.9/100 000 women-years in 2013-2017. From 2007, the incidence among 15- to 19-year-olds rose from 7.0 to 10.0/100 000 women-years in 2015-2017. Cumulative incidence of POI for women under 40 years in 1988-2017 was 478/100 000 women. The relative risk of POI among relatives of women with POI was 4.6 (95% CI 3.3-6.5) compared to relatives of women without POI. POI women tended to have slightly lower socioeconomic status and level of education compared to controls. LIMITATIONS, REASONS FOR CAUTION: For some women with POI, diagnosis or reimbursement may be lacking. However, we presume that these women represent a minority due to the nature of the disease and the economic benefits of reimbursement. Some changes in the incidence of POI can reflect changes in clinical practice and changing treatments and reimbursement criteria. WIDER IMPLICATIONS OF THE FINDINGS: The risk of developing POI is significantly higher in women who have first-degree relatives diagnosed with POI. Raising awareness of the increased risk might lead to earlier diagnosis and initiation of hormonal replacement therapy, possibly preventing adverse effects of low oestrogen levels, such as osteoporosis. STUDY FUNDING/COMPETING INTEREST(S): This work was financially supported by the Oulu University Hospital. H.S. received a grant from Finnish Menopause Society. S.M.S. received a grant from the Finnish Menopause Society, the Finnish Medical Foundation and the Juho Vainio Foundation. The authors do not have any competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Silvén H, Savukoski SM, Pesonen P, et al. Incidence and familial risk of premature ovarian insufficiency in the Finnish female population. Hum Reprod. 2022. PMID: 35134918. doi:10.1093/humrep/deac014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。